Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
Price:
1.89
USD
-4.55%
Market Closed
Market Cap:
$16.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
US |
|
Materialise NV
NASDAQ:MTLS
|
BE |
|
Granada Gold Mine Inc
XTSX:GGM
|
CA |
|
N
|
Nippon Seiro Co Ltd
TSE:5010
|
JP |
|
T
|
Thanapiriya PCL
SET:TNP
|
TH |
|
N
|
Norsyn Crop Technology Co Ltd
SZSE:001231
|
CN |
|
Kingston Financial Group Ltd
HKEX:1031
|
HK |
|
W
|
Warabeya Nichiyo Holdings Co Ltd
TSE:2918
|
JP |
|
D
|
d'Alba Global Co Ltd
KRX:483650
|
KR |
|
A
|
Almondz Global Securities Ltd
NSE:ALMONDZ
|
IN |
|
D
|
Daphne International Holdings Ltd
HKEX:210
|
CN |
|
T
|
TASCO Bhd
KLSE:TASCO
|
MY |
|
S
|
Swarna Securities Ltd
BSE:531003
|
IN |
|
B-SOFT Co Ltd
SZSE:300451
|
CN |
|
Dah Sing Banking Group Ltd
HKEX:2356
|
HK |
|
Mirait One Corp
F:5FO
|
JP |
|
ABOUT YOU Holding SE
XETRA:YOU
|
DE |
|
Superkrane Mitra Utama Tbk PT
IDX:SKRN
|
ID |
|
YPF SA
NYSE:YPF
|
AR |
|
H
|
Harvia Oyj
OMXH:HARVIA
|
FI |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of NRBO.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NRBO
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
NRBO Competitors Multiples
Neurobo Pharmaceuticals Inc Competitors
Neurobo Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
16.3m USD | 0 | -0.6 | 0.2 | 0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
376.8B USD | 6.2 | 90 | 14.9 | 20.7 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD | 109.7 | -1 712.3 | 15 906.4 | -1 796.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.1B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169.2B USD | 5.8 | 19.9 | 12.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.4 | 28.5 | 21.4 | 22.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.1 | 34.7 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
